Geron, Exeter Affiliates Merge to Create Livestock Cloning Shop
By GenomeWeb,
GenomeWeb
| 08. 12. 2008
NEW YORK (GenomeWeb News) - Geron and Exeter Life Sciences said today that Start Licensing, a joint venture between the two firms, and ViaGen, a subsidiary of Exeter, have merged to form a new entity that will focus on animal cloning.
Start manages and licenses a portfolio of intellectual property rights related to animal reproductive technologies, including nuclear transfer cloning technology that was developed at the Roslin Foundation to clone Dolly the sheep. ViaGen is an animal genomics and livestock cloning firm.
Geron and Exeter said that the merger of the firms combines the "full breadth" of Start's nuclear transfer cloning IP with ViaGen's in-house breeding services and expertise in advanced reproductive technologies, including cloning, "to provide a one-stop licensing and operating company" for animal cloning.
"We believe it makes sound business sense to join a patent estate for nuclear transfer that has been tested and is recognized as dominant with a leading operating company in the field," said David Greenwood, Geron's executive vice president and CFO, in a statement.
Jonathan Thatcher, Exeter Life Science's CEO, said that the combined...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Tania Fabo, Truthout | 02.28.2026
The reproductive tech company Orchid recently launched a genetic test that promises a whole genome sequencing report for embryos. It is the first such test commercially available to couples undergoing in vitro fertilization (IVF) and claims to detect things like...
By Pete Shanks
| 02.27.2026
Last month, we published “The Shameful Legacy of Tuskegee” which focused on a proposed experiment in Guinea-Bissau. The study’s plan echoed the notorious Tuskegee disaster, withholding safe, effective vaccines against hepatitis B from some newborns while inoculating others. It was to be financed by the U.S. but performed by a controversial Danish team. That project provoked a multi-national outcry, leading to a remarkable response from the World Health Organization:
WHO has significant concerns regarding the study’s scientific...
By Jenn White, NPR | 02.26.2026
